2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1888

There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1387

Thoracic Paravertebral Masses and IgG4-Related Disease: Report of 8 Cases and Review of the Literature

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1412

Thread Carpal Tunnel Release (TCTR) Completely Divides the Transverse Carpal Ligament (TCL) As Well As Open and Endoscopic Surgery: A Cadaver Study

Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 1637

TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1336

To PET or Not to PET in General Rheumatology Practice

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1487

Tocilizumab in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Who Have Failed to Disease-Modifying Antirheumatic Drugs: Long Term Results of the Brazilian Cohort

Quality Measures and Quality of Care Poster Session (ARHP): Clinical Practice/Patient Care

9:00AM-11:00AM: Abstract Number: 1980

Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1978

Tocilizumab in Refractory Large Vessel Vasculitis with Aorta Involvement. Study on 10 Patients Evaluated By Positron Emission Tomoghraphy

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1650

Tocilizumab Monotherapy in Early Rheumatoid Arthritis: Data from Two Phase 3 Randomized Controlled Trials

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1405

Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1645

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1834

Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1529

Trabecular Bone Score in Early Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1543

Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1159

Transcription Factor SOX5 Promotes Rheumatoid Arthritis Synovial Fibroblast Migration and Invasion By Regulating MMP9 Expression

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].